Allylmercaptocaptopril: a new antihypertensive drug

详细信息    查看全文

• 作者：Talia Miron ; Aharon Rabinkov ; Edna Peleg ; Talma Rosenthal ; David Mirelman ; Meir Wilchek
• 刊名：American Journal of Hypertension
• 出版年：2004
• 出版时间：January 2004
• 年：2004
• 卷：17
• 期：1
• 页码：71-73
• 全文大小：136 K

文摘

Allylmercaptocaptopril (CPSSA) was synthesized by reacting captopril with pure allicin. Fructose-induced hypertensive groups of rats were fed a fructose-rich diet for 3 weeks, and then received the diet plus either CPSSA (40 to 56 mg or 138 to 194 μmol/L/kg/d) or captopril (80 mg or 369 μmol/L/kg/d) for 2 more weeks. CPSSA (both doses) significantly lowered blood pressure (BP) from 153.4 to 120.8 mm Hg (P < .005). Captopril gave similar results, lowering BP from 150.7 to 123 mm Hg (P < .005). CPSSA also decreased the high levels of triglycerides to normal. The new stable compound allylmercaptocaptopril combines the beneficial properties of captopril and allicin and is a potential candidate for antihypertensive drug therapy.